Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2017

01-02-2017 | Short Communication

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report

Authors: Antonella Caivano, Francesco La Rocca, Vittorio Simeon, Marco Girasole, Simone Dinarelli, Ilaria Laurenzana, Angelo De Stradis, Luciana De Luca, Stefania Trino, Antonio Traficante, Giovanni D’Arena, Giovanna Mansueto, Oreste Villani, Giuseppe Pietrantuono, Luca Laurenti, Luigi Del Vecchio, Pellegrino Musto

Published in: Cellular Oncology | Issue 1/2017

Login to get access

Abstract

Purpose

The use of extracellular vesicles (EVs) from body fluids as “liquid biopsies” is emerging as a promising approach for the diagnosis, prognosis and therapeutic monitoring of cancer patients. MicroRNA-155 (miR155), a non-coding transcript of the B-cell integration cluster (BIC) gene, has been reported to play a critical role in the pathogenesis of several types of hematologic malignancies (HMs) in which high miR155 levels have been found. At yet, however, the EV miR155 level and its putative clinical relevance in sera of HM patients have not been reported.

Methods

EVs from sera of representative patients with eight different HMs and healthy subjects (controls) were isolated using differential centrifugation. The identity and quality of the EVs were verified by atomic force and transmission electron microscopy. The EV miR155 levels were measured by quantitative RT-PCR. The sensitivity, specificity and area under the curve (AUC) of differences in EV miR155 levels were determined using ROC curve analyses.

Results

We found that the EV miR155 levels were significantly higher in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and Waldenström’s macroglobulinemia (WM) cases compared to controls. Conversely, we found that the EV miR155 levels were significantly lower in myelodysplastic syndrome (MDS) and multiple myeloma (MM) cases. No differences were found in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or Hodgkin’s Lymphoma (HL) cases compared to controls. EV miR155 ROC curve analyses revealed significantly different patterns in CLL and AML cases compared to controls, and in AML cases compared to MDS cases (p = 0.004, p = 0.01 and p = 0.04, respectively). In addition, we found that high EV miR155 levels correlated with high white blood cell counts in AML patients.

Conclusion

Our data indicate that EV miR155 may serve as an attractive new, non-invasive diagnostic biomarker in human hematologic malignancies.
Appendix
Available only for authorised users
Literature
1.
2.
J. Hayes, P. P. Peruzzi, S. Lawler, MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20, 460–469 (2014)CrossRefPubMed
3.
I. Fkih, M’hamed, M. Privat, F. Ponelle, F. Penault-Llorca, a. Kenani, Y.J. Bignon, identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. Cell Oncol 38, 433–442 (2015)CrossRef
4.
V. Taucher, H. Mangge, J. Haybaeck, R. N. A. Non-coding, In pancreatic cancer: challenges and opportunities for clinical application. Cell Oncol 39, 295–318 (2016)CrossRef
5.
M. Shahjahani, J. Mohammadiasl, F. Noroozi, M. Seghatoleslami, S. Shahrabi, F. Saba, N. Saki, Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol 38, 93–109 (2015)CrossRef
6.
B. Ortiz-Quintero, Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif 49, 281–303 (2016)CrossRefPubMed
7.
M. Vitiello, A. Tuccoli, L. Poliseno, Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol 38, 17–28 (2015)CrossRef
8.
D. L. Zhaolei Cui, Circulating miRNAs: potential biomarkers for diagnosis and prognosis prediction of hematological malignancies. J Leuk 2, 1–15 (2014)CrossRef
9.
M. Yáñez-Mó, P.R.M. Siljander, Z. Andreu, A. Bedina Zavec, F.E. Borràs, E.I. Buzás, K. Buzas, E. Casal, F. Cappello, J. Carvalho, E. Colás, A. Cordeiro-da Silva, S. Fais, J.M. Falcon-Perez, I.M. Ghobrial, B. Giebel, M. Gimona, M. Graner, I. Gursel, M. Gursel, N.H.H. Heegaard, A. Hendrix, P. Kierulf, K. Kokubun, M. Kosanovic, V. Kralj-Iglic, E. M. Krämer-Albers, S. Laitinen, C. Lässer, T. Lener, E. Ligeti, A. Linē, G. Lipps, A. Llorente, J. Lötvall, M. Manček-Keber, A. Marcilla, M. Mittelbrunn, I. Nazarenko, E.N.M. Nolte-Hoen‘t, T.A. Nyman, L. O’Driscoll, M. Olivan, C. Oliveira, É. Pállinger, H.A. del Portillo, J. Reventós, M. Rigau, E. Rohde, M. Sammar, F. Sánchez-Madrid, N. Santarém, K. Schallmoser, M. Stampe Ostenfeld, W. Stoorvogel, R. Stukelj, S.G. Van der Grein, M.H. Vasconcelos, M.H.M. Wauben, O. De Wever, Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4, 319–325 (2015)
10.
S. Raimondo, C. Corrado, L. Raimondi, G. De Leo, R. Alessandro, Role of extracellular vesicles in hematological malignancies. Biomed Res Int 2015, 1–9 (2015)
11.
L. M. Desrochers, M. A. Antonyak, R. A. Cerione, Extracellular vesicles: satellites of information transfer in cancer and stem cell biology. Dev Cell 37, 301–309 (2016)CrossRefPubMed
12.
L. De Luca, S. Trino, I. Laurenzana, V. Simeon, G. Calice, S. Raimondo, M. Podestà, M. Santodirocco, L. Di Mauro, F. La Rocca, A. Caivano, A. Morano, F. Frassoni, D. Cilloni, L. Del Vecchio, P. Musto, MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget 7, 6676–6692 (2015)PubMedCentral
13.
I. Tatischeff, Cell-derived extracellular vesicles open new perspectives for cancer research. Cancer Res Front 1, 208–224 (2015)CrossRef
14.
A. Caivano, I. Laurenzana, L. De Luca, F. La Rocca, V. Simeon, S. Trino, F. D’Auria, A. Traficante, M. Maietti, T. Izzo, G. D’Arena, G. Mansueto, G. Pietrantuono, L. Laurenti, P. Musto, L. Del Vecchio, High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumour Biol 36, 9739–3752 (2015)CrossRefPubMed
15.
I. Faraoni, F. R. Antonetti, J. Cardone, E. Bonmassar, miR-155 gene: a typical multifunctional microRNA. Biochem. Biophys. Acta 1792, 497–505 (2009)PubMed
16.
17.
T. S. Elton, H. Selemon, S. M. Elton, N. L. Parinandi, Regulation of the MIR155 host gene in physiological and pathological processes. Gene 532, 1–12 (2013)CrossRefPubMed
18.
R. W. Georgantas, R. Hildreth, S. Morisot, J. Alder, C. G. Liu, S. Heimfeld, G. A. Calin, C. M. Croce, C. I. Civin, CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A 104, 2750–2755 (2007)CrossRefPubMedPubMedCentral
19.
20.
M. Girasole, S. Dinarelli, G. Boumis, Structural, morphological and nanomechanical characterisation of intermediate states in the ageing of erythrocytes. J Mol Recognit 25, 285–291 (2012)CrossRefPubMed
21.
M. Colombo, G. Raposo, C. Théry, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30, 255–289 (2014)CrossRefPubMed
22.
D. Zocco, P. Ferruzzi, F. Cappello, W. P. Kuo, Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Front. Oncologia 4, 267–274 (2014)
23.
A. Gallamini, M. Hutchings, S. Ramadan, Clinical presentation and staging of Hodgkin lymphoma. Semin Hematol 53, 148–154 (2016)CrossRefPubMed
24.
Y.-Y. Yeh, H. G. Ozer, A. M. Lehman, K. Maddocks, L. Yu, A. J. Johnson, J. C. Byrd, Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 125, 3297–3305 (2015)CrossRefPubMedPubMedCentral
25.
A. Ferrajoli, T. D. Shanafelt, C. Ivan, M. Shimizu, K. G. Rabe, N. Nouraee, M. Ikuo, A. K. Ghosh, S. Lerner, L. Z. Rassenti, L. Xiao, J. Hu, J. M. Reuben, S. Calin, M. J. You, J. T. Manning, W. G. Wierda, Z. Estrov, S. O’Brien, T. J. Kipps, M. J. Keating, N. E. Kay, G. A. Calin, Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 122, 1891–1899 (2013)CrossRefPubMedPubMedCentral
26.
S. A. Parikh, T. D. Shanafelt, Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol 43, 233–240 (2016)CrossRefPubMed
27.
A. Sacco, Y. Zhang, P. Maiso, S. Manier, G. Rossi, S. P. Treon, I. M. Ghobrial, A. M. Roccaro, Aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 13, 205–210 (2013)CrossRefPubMed
28.
A. M. Roccaro, A. Sacco, C. Chen, J. Runnels, X. Leleu, F. Azab, A. K. Azab, X. Jia, H. T. Ngo, M. R. Melhem, N. Burwick, L. Varticovski, C. D. Novina, B. J. Rollins, K. C. Anderson, I. M. Ghobrial, microRNA aberrations in Waldenström macroglobulinemia. Blood 113, 4391–4402 (2009)CrossRefPubMedPubMedCentral
29.
P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. G. Sanz, S. P. Treon, V. Leblond, R. A. Kyle, B. Barlogie, G. Merlini, International prognostic scoring system for Waldenström macroglobulinemia. Blood 113, 4163–4170 (2009)CrossRefPubMed
30.
N. I. Hornick, J. Huan, B. Doron, N. A. Goloviznina, J. Lapidus, B. H. Chang, P. Kurre, Serum exosome microRNA as a minimally-invasive early biomarker of AML. Sci Report 5, 11295–11307 (2015)CrossRef
31.
H. J. M. de Jonge, P. J. M. Valk, E. S. J. M. de Bont, J. J. Schuringa, G. Ossenkoppele, E. Vellenga, G. Huls, Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica 96, 1310–1317 (2011)CrossRefPubMedPubMedCentral
32.
I. De Kouchkovsky, M. Abdul-Hay, Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6, e441 (2016)
33.
D. W. Lee, M. Futami, M. Carroll, Y. Feng, Z. Wang, M. Fernandez, Z. Whichard, Y. Chen, S. Kornblau, E. J. Shpall, C. E. Bueso-Ramos, S. J. Corey, Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene 31, 4085–4094 (2012)CrossRefPubMed
34.
A. Pons, B. Nomdedeu, A. Navarro, A. Gaya, B. Gel, T. Diaz, S. Valera, M. Rozman, M. Belkaid, E. Montserrat, M. Monzo, Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 50, 1854–1859 (2009)CrossRefPubMed
35.
P. L. Greenberg, N. S. Young, N. Gattermann, Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465 (2012)CrossRefPubMedPubMedCentral
36.
D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz, M. M. Le Beau, C. D. Bloomfield, M. Cazzola, J. W. Vardiman, Reclassifying myelodysplastic syndromes: what’s where in the new WHO and why. Blood 127, 2391–2405 (2016)CrossRefPubMed
37.
N. Gangat, M. M. Patnaik, A. Tefferi, Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol 91, 76–89 (2015)CrossRef
38.
P. Krzeminski, M.E. Sarasquete, I. Misiewicz-Krzeminska, R. Corral, L.A. Corchete, A.A. Martín, R. Garcia-Sanz, J.F. San-Miguel, N. C. Gutierrez, Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochim Biophys Acta 1849, 353–366 (2015)
39.
M. Feng, X. Luo, C. Gu, J. Fei, Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. J Drug Target 23, 59–66 (2014)CrossRefPubMed
40.
M. Lionetti, M. Biasiolo, L. Agnelli, K. Todoerti, L. Mosca, S. Fabris, G. Sales, G. L. Deliliers, S. Bicciato, L. Lombardi, S. Bortoluzzi, A. Neri, Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114, e20 (2009)CrossRefPubMed
Metadata
Title
MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report
Authors
Antonella Caivano
Francesco La Rocca
Vittorio Simeon
Marco Girasole
Simone Dinarelli
Ilaria Laurenzana
Angelo De Stradis
Luciana De Luca
Stefania Trino
Antonio Traficante
Giovanni D’Arena
Giovanna Mansueto
Oreste Villani
Giuseppe Pietrantuono
Luca Laurenti
Luigi Del Vecchio
Pellegrino Musto
Publication date
01-02-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0300-x

Other articles of this Issue 1/2017

Cellular Oncology 1/2017 Go to the issue

Review

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

Report

Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report

Original Paper

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia

Original Paper

Collective cell migration of thyroid carcinoma cells: a beneficial ability to override unfavourable substrates

Original Paper

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma

Original Paper

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits